Publication | Closed Access

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

HepatologyNon-metastatic Hepatocellular CarcinomaTransarterial ChemoembolisationMedicinePharmacologyPharmacotherapyLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular Carcinoma